Alivus Life Sciences
Stock Snapshot
Price Performance
Vista Outlook
View Technicals Analysis →Basis of our Recommendation
Alivus Life Sciences is positioned for stable growth, bolstered by management's strategic focus on diversification and resilience under Nirma's ownership. Recent commentary highlights a significant capacity expansion plan, with total reactor capacity expected to more than double by FY28, which is crucial for meeting anticipated demand in regulated markets. The company aims to sustain EBITDA margins between 30-32%, supported by a robust pipeline of high-potent APIs and a recovering CDMO segment. Vista's financial outlook reflects these developments, projecting high single-digit revenue growth for FY27 and stable margins, aligning with the company's strategic initiatives. However, challenges such as geopolitical tensions and supply chain disruptions remain pertinent. Over the next 12-24 months, key opportunities include the successful launch of new products and geographical expansion, while watchpoints include the potential impact of raw material cost fluctuations and the pace of capacity ramp-up. Overall, Alivus's focus on high-quality, less commoditized products positions it well in a competitive landscape, although external pressures could temper growth expectations
Why We Like This Stock
- Management's confidence in sustaining EBITDA margins of 30-32% through improved operating leverage and new product contributions
- Significant capacity expansion plans, with total reactor capacity projected to more than double by FY28, enhancing production capabilities
- A robust pipeline of high-potent APIs and a recovering CDMO segment are expected to drive future revenue growth
Things To Watch Out For
- Ongoing geopolitical conflicts and global demand uncertainties pose risks to operational stability and growth
- Supply chain disruptions and raw material cost fluctuations could impact margins and production timelines
- The GPL business has experienced de-growth, which may affect overall revenue performance if not offset by growth in the non-GPL segment
Key Parameters
Financial Snapshot
| Actuals | Forecast | ||||
|---|---|---|---|---|---|
| FY24 | FY25 | FY26 | FY27 | FY28 | |
| Revenue (Cr.) | 2,283 | 2,387 | 2,552 | 2,552 | 2,699 |
| Profit Before Tax (Cr.) | 632 | 648 | 777 | 843 | 874 |
| PBT Margin | 27.7% | 27.1% | 3044.7% | 33.0% | 32.4% |
| Net Profit (Cr.) | 480 | 488 | 586 | 636 | 659 |
| Earnings Per Share | 39.1 | 39.8 | 47.7 | 51.8 | 53.7 |
Analyst Recommendations
| Broker | Recommendation | Target Price | Date |
|---|---|---|---|
| Kotak Securities | ▲ Buy | 1,315 | 30-Jun-2026 |
Company Overview
Show Company Profile
Alivus Life Sciences Limited develops, manufactures, and markets active pharmaceutical ingredients in India, Japan, Europe, North and Latin America, and internationally. It offers various APIs, such as olmesartan, telmisartan, solifenacin, sitagliptin, zonisamide, rosuvastatin, amiodarone, ezetimibe, lithium carbonate, oxcarbazepine, mirabegron, atovaquone, etoricoxib, remogliflozin, cabozantinib, and palbociclib for various therapeutic areas, including cardiovascular disease, central nervous system disorders, diabetes, gastrointestinal health, oncology, pain management, immunosuppressant, respiratory and ophthalmologic agents, urology, and anti-infectives. The company also provides contract development and manufacturing services to a range of multinational corporations and specialty companies. It exports its products. The company was formerly known as Glenmark Life Sciences Limited and changed its name to Alivus Life Sciences Limited in December 2024. The company was founded in 2001 and is based in Mumbai, India. Alivus Life Sciences Limited is a subsidiary of Nirma Limited.